Vertebral fracture status and the WHO risk factors for predicting osteoporotic fracture risk

Vertebral fractures are the most common osteoporotic fracture, and patients with prevalent vertebral fractures have a greater risk of future fractures. However, radiographically determined vertebral fractures are not identified as a distinct risk factor in the World Health Organization (WHO) fracture risk assessment tool. The objective of this study [1] was to evaluate and compare potential risk factors including morphometric spine fracture status and the WHO risk factors for predicting 5-y fracture risk. It was hypothesized that spine fracture status provides prognostic information in addition to consideration of the WHO risk factors alone. A randomly selected, population-based community cohort of 2761 noninstitutionalized men and women > 50 y of age living within 50 km of one of nine regional centers was enrolled in the Canadian Multicentre Osteoporosis Study (CaMOS), a prospective and longitudinal cohort study following subjects for 5 y. Prevalent and incident spine fractures were identified from lateral spine radiographs. Incident nonvertebral fragility fractures were determined by an annual, mailed fracture questionnaire with validation, and nonvertebral fragility fracture was defined by investigators as a fracture with minimal trauma.
Read the rest of this entry »

Vertebroplasty for osteoporotic vertebral fractures: is it efficient?

Vertebroplasty is commonly used to treat painful, osteoporotic vertebral compression fractures. Two recent studies [1,2] evaluated the efficiency of this procedure. In a multicenter trial [1], the authors randomly assigned 131 patients who had one to three painful osteoporotic vertebral compression fractures to undergo either vertebroplasty or a simulated procedure without cement (control group). The primary outcomes were scores on the modified Roland–Morris Disability Questionnaire (RDQ) (on a scale of 0 to 23, with higher scores indicating greater disability) and patients’ ratings of average pain intensity during the preceding 24 hours at 1 month (on a scale of 0 to 10, with higher scores indicating more severe pain). Patients were allowed to cross over to the other study group after 1 month.

All patients underwent the assigned intervention (68 vertebroplasties and 63 simulated procedures). The baseline characteristics were similar in the two groups. At 1 month, there was no significant difference between the vertebroplasty group and the control group in either the RDQ score or the pain rating. Both groups had immediate improvement in disability and pain scores after the intervention. Although the two groups did not differ significantly on any secondary outcome measure at 1 month, there was a trend toward a higher rate of clinically meaningful improvement in pain (a 30% decrease from baseline) in the vertebroplasty group (64% vs. 48%, P=0.06). At 3 months, there was a higher crossover rate in the control group than in the vertebroplasty group (43% vs 12%, P<0.001). There was one serious adverse event in each group.

The second study [2] was also a multicenter, randomized, double-blind, placebo-controlled trial in which 78 participants with one or two painful osteoporotic vertebral fractures that were of less than 12 months’ duration and unhealed, as confirmed by magnetic resonance imaging, were randomly assigned to undergo vertebroplasty or a sham procedure. Similar improvements were seen in both groups with respect to pain at night and at rest, physical functioning, quality of life, and perceived improvement.

In conclusion, improvements in pain and pain-related disability associated with osteoporotic compression fractures in patients treated with vertebroplasty were similar to the improvements in a control group. These studies found no beneficial effect of vertebroplasty as compared with a sham procedure in patients with painful osteoporotic vertebral fractures, up to 6 months after treatment.

1. Kallmes DF et al. N Engl J Med. 2009; 361:569-579.
2. Buchbinder R et al. N Engl J Med. 2009; 361:557-568.

Early smoking is associated with peak bone mass and prevalent fractures in young, healthy men

Smoking is associated with lower areal bone mineral density and higher fracture risk, although most evidence has been derived from studies in elderly subjects. This study [1] investigates smoking habits in relation to areal and volumetric bone parameters and fracture prevalence in young, healthy males at peak bone mass. Healthy male siblings (n=677) at the age of peak bone mass (25 to 45 years) were recruited in a cross-sectional population-based study. Trabecular and cortical bone parameters of the radius and cortical bone parameters of the tibia were assessed using peripheral quantitative computed tomography (pQCT). Areal bone mass was determined using dual energy X-ray absorptiometry (DXA). Sex steroids and bone markers were determined using immunoassays. Prevalent fractures and smoking habits were assessed using questionnaires.

Self-reported fractures were more prevalent in the current and early smokers than in the never smokers (P<.05), with a fracture prevalence odds ratio for early smokers of 1.96 after adjustment for age, weight, educational level, and alcohol use and exclusion of childhood fractures. Current smoking was associated with a significantly larger endosteal circumference and a decreased cortical thickness at the tibia.
Read the rest of this entry »

Effect of osteoporosis treatment on mortality

Fragility fractures cause significant morbidity and mortality. Effective osteoporosis treatment can reduce fracture incidence, but it is not clear whether it reduces mortality. The aim of this meta-analysis study [1] was to determine whether effective osteoporosis treatment reduces mortality. The authors searched Medline and the Cochrane Central Register of Trials prior to September 2008, as well as 2000–2008 American Society for Bone and Mineral Research conference abstracts. Eligible studies were randomized placebo-controlled trials of approved doses of medications with proven efficacy in preventing both vertebral and nonvertebral fractures, in which the study duration was longer than 12 months and there were more than 10 deaths. Trials of estrogen and selective estrogen receptor modulators were specifically excluded. Data were extracted from the text of the retrieved articles, published meta-analyses, or the Food and Drug Administration web site.

Read the rest of this entry »

QFractureScores for predicting risk of osteoporotic fracture

The objective of this study [1] was to develop and validate two new fracture risk algorithms (QFractureScores) for estimating the individual risk of osteoporotic fracture or hip fracture over 10 years. For this purpose, the authors used a prospective open cohort study with routinely collected data from 357 general practices to develop the scores and from 178 practices to validate the scores, in England and Wales. Participants were 1 183 663 women and 1 174 232 men aged 30 to 85 in the derivation cohort, who contributed 7 898 208 and 8 049 306 person years of observation, respectively. There were 24 350 incident diagnoses of osteoporotic fracture in women and 7934 in men, and 9302 incident diagnoses of hip fracture in women and 5424 in men. The main outcome measures were first (incident) diagnosis of osteoporotic fracture (vertebral, distal radius, or hip) and incident hip fracture recorded in general practice records.

Read the rest of this entry »